First Read: China Pharmaceutical Retail Sector "Will regulations disrupt..."

Research evidence excerpt

First Read: China Pharmaceutical Retail Sector "Will regulations disrupt..."

Global Research

26 May 2026ab

First Read

EquitiesChina Pharmaceutical Retail Sector

Will regulations disrupt online penetration? China

Healthcare

Henry Liu, CFA

What happened? Analyst

Shares of offline pharmacies and healthcare e-commerce companies fell 7-10% last henry-za.liu@ubs.com

week amid concerns over tightening regulations. On May 25, the National Medical +86-105-832 8509

Products Administration (NMPA) issued Compliance Guidelines for Online Prescription Chen Chen, PhD

Drugs Sales, outlining specific requirements for quality control, information disclosure, Analyst

pharmaceutical services, procurement processes, early risk detection, and drug sales to S1460520100001

minors. The NMPA's next steps include cracking down on illegal activities, integrating chen-zb.chen@ubs.com

+86-10-5832 8201online/offline supervision, enhancing information disclosure, and reinforcing oversight

of third-party platforms. As we understand, the finalized guidelines show no material Judy Xie

changes vs the Sep 2025 consultation draft. Other recent regulatory events include: on Associate

May 14, media reports of tighter regulation on GLP-1 sales in retail channels (see our S1460125100001

judy.xie@ubs.comtake); and on May 16, the National Healthcare Security Administration held regulatory

+86-105-832 8006

talks with several leading offline pharmacy chains (see our take).

Company feedback - limited impact for compliant sellers

Feedback from listed companies and our channel checks suggests a very different

picture from what current share prices imply. The impact appears limited to online

prescriptions of GLP-1s for weight-loss indications only, rather than all GLP-1s (eg, those